Letrovil 5 Tablet contains Letrozole 5 mg, an aromatase inhibitor primarily used in the management of hormone receptor-positive breast cancer in postmenopausal women. Letrozole functions by inhibiting the aromatase enzyme, which is responsible for the peripheral conversion of androgens to estrogens. By reducing estrogen levels, Letrovil 5 effectively decreases tumor growth that depends on estrogen stimulation. It is commonly prescribed as adjuvant therapy following surgery or radiation, as well as for advanced or metastatic breast cancer cases. The standard dosage and duration of treatment should be determined by a healthcare professional based on individual patient needs and response. Letrovil 5 is contraindicated in premenopausal women, during pregnancy, and in patients with hypersensitivity to Letrozole or any excipients in the formulation. Common side effects may include hot flashes, joint pain, fatigue, and nausea, while more serious adverse effects such as bone density loss require monitoring during prolonged therapy. Patients should inform their physician of any concurrent medications to avoid potential drug interactions. Regular follow-up and assessment of bone health, liver function, and lipid profiles are recommended to ensure safe and effective treatment with Letrovil 5 Tablet.